Actuate Therapeutics

ACTU

시가총액 US$1453만

CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one meetings during the conference.

CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, today announced new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G12D-selective inhibitor, and daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in pancreatic ductal adenocarcinoma (PDAC), including models resistant to FOLFIRINOX chemotherapy. The studies were conducted in collaboration with investigators at Northwestern University and the Mayo Clinic.

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham  - Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma - Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses and increased mOS versus FOLFIRINOX alone or in combination with losartan - Elraglusib treatment was well tolerated when used in combination with either GnP or FOLFIRINOX CHICAGO and FORT WORTH, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that two presentations were given at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations featured post-hoc efficacy and biomarker analyses from the randomized Phase 2 study (NCT03678883), along with clinical data from a Phase 2 study conducted at Mass General Brigham Cancer Institute of elraglusib in combination with FOLFIRINOX (FFX) and the TGF-β inhibitor losartan in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use FDA cleared IND for Phase 1/2 study of oral elraglusib in advanced cancer patients, with focus on metastatic melanoma, NSCLC, colorectal, and pancreatic cancers with initiation planned for 2H 2026 Elraglusib plus RAS inhibitor preclinical results expected in mid-2026 Industry veteran Martin Huber, MD, joins Board of Directors CHICAGO and FORT WORTH, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced key initiatives to advance and expand the potential of the elraglusib development program. Actuate is prioritizing the development of the elraglusib oral tablet formulation, which is intended to enhance patient convenience, broaden potential clinical utility, and improve the pharmacokinetic exposure of elraglusib across multiple oncology indications.

Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.

Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies

Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo ​alone, according to results of a mid-stage trial.

CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in  Nature Medicine from a randomized phase 2 clinical trial (NCT03678883) evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer. The peer-reviewed paper (DOI: 10.1038/s41591-026-04327-4), entitled “Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial” is available here.